ARGS Gets New Lease Of Life, RARE Surges On Study Results, NVLS Abuzz

Shares of Ultragenyx Pharmaceutical Inc. (RARE) were up more than 18% in extended trading on Tuesday, following positive 24-week data from its phase III study of Burosumab (KRN23) in adults with X-linked hypophosphatemia.

from RTT - Biotech http://ift.tt/2o2lv8q
via IFTTT